Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
J Egypt Natl Canc Inst. 2010 Jun;22(2):113-22.

Outcome and prognostic factors of uterine sarcoma in 59 patients: single institutional results.

Author information

  • 1The Departments of Surgical Oncology , National Cancer Institute, Cairo University, Egypt.



Uterine corpus sarcomas are rare heterogeneous tumors characterized by rapid progression and poor response to treatment. This series investigated treatment options, relapse pattern, survival and prognostic factors.


A total of 59 patients were treated in the National Cancer Institute, Cairo University, (2000-2007). Leiomyosarcoma accounted for 42.2% followed by carcinosarcoma (35.5%) and endometrial stromal sarcoma (18.6%). 40.7% had FIGO stage I disease, 30.5% were II, 16.9% were III and 11.9% were IV. Surgery was the primary line of treatment for all cases with total abdominal hysterectomy and bilateral salpingoophorectomy in 88% of cases and 12% had less extensive surgery. Twenty-four (40.7%) patients had surgery alone, 24 (40.7%) had surgery and radiotherapy, 7 (11.9%) had surgery and chemo-irradiation and 4 (6.7%) had surgery and chemotherapy.


After 27.4 months mean follow-up (range: 2-69), relapses were detected in 32 patients (59.2%) including 19 (59%) systemic metastases. Stage, adjuvant irradiation, tumor size, myometrial invasion, vascular and cervix invasion were significant factors in univariate analysis; nevertheless, multivariate prognostic factors were only stage (p=0.04) and adjuvant irradiation (p=0.01). 5-year cumulative disease free survival for stage I was 63.6%, 41.2% for stage II, 10% for stage III and 0% in stage IV. Neither extent of surgery, chemotherapy, histologic type or grade had significant effect on survival. Adjuvant radiotherapy offered 62% 2-year cumulative overall survival versus 22% for surgery alone and surgery with chemotherapy. Salvage surgery for isolated relapses was performed for 9/32 recurrent patients (28%) including 5 lung metastatectomies and 4 local pelvic resections. Mean survival after pulmonary resections was 7.4 months (6-14).


Diagnosis of uterine sarcoma is in itself a poor prognostic factor. Complete cytoreductive surgery and adjuvant radiotherapy is essential for local control, provided tumor is limited to the uterus. Adjuvant irradiation showed survival benefit.


Uterine cancer - Uterine sarcoma - Uterine sarcoma treatment - Sarcoma irradiation - Sarcoma prognosis.

[PubMed - in process]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for The Egyptian National Cancer Institute
    Loading ...
    Write to the Help Desk